CELC Stock Holds Trend As Opaque Insider Filings Hit Tape
Celcuity Inc. (CELC) surged over 6.5% due to positive breast cancer trial results, despite opaque insider filings. Two Form 4 filings indicated changes in beneficial ownership but lacked crucial details like transaction size or direction, making it difficult for traders to assess their impact. The article emphasizes that despite the vague insider activity, CELC's strong price action, existing cash runway, and ongoing research funding are the primary drivers for traders.
Precision Trading with Celcuity Inc. (CELC) Risk Zones
This article provides a precision trading analysis for Celcuity Inc. (CELC) using AI models, highlighting strong sentiment across all horizons and an exceptional risk-reward setup. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key support/resistance levels to optimize trading decisions.
Is Celcuity (CELC) Undervalued After Its Removal From Major Russell Indices?
Celcuity (CELC) was recently removed from several Russell indices, influencing trading flows. Despite this, its share price has shown strong momentum, with analysts forecasting significant revenue by 2029 and a fair value suggesting it is undervalued. The article presents two valuation perspectives: one based on future earnings predicting a 33% undervaluation and another using a DCF model showing an 88.5% discount, both contingent on successful future developments.
CELC - Celcuity Inc Options
This article provides detailed financial data and performance metrics for Celcuity Inc. (CELC). It includes key financial ratios, stock performance over various periods, insider and institutional ownership, and analyst recommendations. The data highlights the company's valuation, profitability, and short interest, offering a comprehensive snapshot for potential investors.
Price to earnings forward of Celcuity Inc. – NASDAQ:CELC
This article provides access to the "Price to earnings forward" financial metric for Celcuity Inc. (NASDAQ: CELC) on the TradingView platform. It appears to be a stub or a data point within a larger financial analysis tool, showcasing the company's ticker and market. The content primarily consists of navigation and platform features, rather than a detailed report.
Price to sales forward of Celcuity Inc. – DUS:7VR
This article provides the "Price to sales forward" metric for Celcuity Inc. (DUS:7VR) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The page also offers overview information, financials, news, community, technicals, and forecasts for the company.
Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 2000 Value Benchmark
Celcuity Inc. (NasdaqCM: CELC) has been dropped from the Russell 2000 Value Benchmark, as well as the Russell Microcap Value Benchmark Index, Russell 3000E Growth Benchmark, Russell Microcap Index, and Russell 3000E Index. The company is a clinical-stage biotechnology firm developing targeted therapies for solid tumors, with its lead candidate, gedatolisib, currently in Phase III clinical trials for advanced breast cancer. Despite recent news about the Phase III trial and convertible notes offerings, the company has seen multiple index removals.
Enterprise value to revenue forward of Celcuity Inc. – NASDAQ:CELC
This article focuses on the enterprise value to revenue forward metric for Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data point presented within a TradingView context, indicating no trades and providing an overview of the company's financial information. The content primarily lists various functionalities and disclaimers from the TradingView platform.
Enterprise value to EBITDA forward of Celcuity Inc. – MUN:7VR
The article displays the enterprise value to EBITDA forward for Celcuity Inc. (MUN:7VR) on the Munich Stock Exchange. It focuses solely on this financial metric, indicating that the market was closed with no trades at the time of viewing.
Enterprise value to revenue forward of Celcuity Inc. – MUN:7VR
This article provides financial information for Celcuity Inc. (MUN:7VR) listed on the Munich Stock Exchange, specifically focusing on its enterprise value to forward revenue. It appears to be a financial data snippet from a larger platform, offering an overview of the company's financial metrics. The content itself is minimal, primarily a heading indicating the financial data point.
Enterprise value to EBIT forward of Celcuity Inc. – NASDAQ:CELC
This article focuses on the enterprise value to EBIT forward of Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data page from TradingView, displaying stock information and financial metrics for the company. The content primarily highlights the "Enterprise value to EBIT forward" metric for Celcuity Inc.
Price to book forward of Celcuity Inc. – MUN:7VR
This article presents the "Price to book forward" financial metric for Celcuity Inc. (MUN:7VR), indicating its value and change over a period. It highlights that the information is 'Made by humans' and uses market data from ICE Data Services and reference data from FactSet.
Celcuity Inc. Actuals & Estimates (HAM:7VR)
This article provides an overview of Celcuity Inc. (7VR) stock performance, analyst estimates, and financial data on the Hamburg Stock Exchange. It includes details on the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along with frequently asked questions about the company's financials and stock trading.
A2JAAX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Celcuity Inc. (A2JAAX) stock, including its current price, analyst ratings, and future price predictions. It details the company's financials, such as EPS, revenue, market capitalization, and upcoming earnings dates. The article also addresses frequently asked questions about the stock's performance, volatility, and how to trade it.
Celcuity Inc (CELC) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Celcuity Inc (CELC), detailing its price momentum, support and resistance levels, and various technical indicators like MACD, RSI, and moving averages. The stock currently has a price momentum score of 6.84 and is trading between a resistance level of 126.20 and a support level of 65.94. Based on the analysis, the overall signal for CELC is currently a "Sell."
Celcuity Inc (CELC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Celcuity Inc (CELC), including its business segments and regional revenue and profit contribution. However, the article indicates that the relevant data for these categories has not yet been disclosed by the company. It serves as a placeholder for future financial details.
Celcuity shares fall despite strong phase 3 breast cancer trial data (CELC)
Despite positive Phase 3 trial data for its breast cancer drug inavolisib, Celcuity's (CELC) shares experienced a significant decline. The trial, conducted in collaboration with Roche, showed a statistically significant improvement in progression-free survival for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. However, the market reaction suggests investor concerns or unmet expectations regarding the trial's full implications or future prospects.
Celcuity Inc (CELC) Earnings Forecast: Future EPS & Revenue Growth Estimates
Celcuity Inc (CELC) has an earnings forecast score of 8.83, ranking it 50th in the Biotechnology & Medical Research industry. Analysts have an average price target of $108.00, with a consensus "Buy" rating based on 12 analysts. The company's previous quarter EPS was USD -0.97, meeting expectations, and the next quarter's EPS is projected to be USD -1.11.
Should Celcuity’s $500 Million Convertible Notes and VIKTORIA-1 Data Shift the CELC Investment Thesis Require Action From Celcuity (CELC) Investors?
Celcuity Inc. recently priced a $500 million convertible senior notes offering and reported positive Phase 3 VIKTORIA-1 data for gedatolisib in PIK3CA mutant advanced breast cancer. While the financing strengthens the company's runway, it also introduces future dilution and repayment obligations. Investors need to assess how these developments, alongside forecasts predicting significant revenue and earnings growth, impact the overall investment thesis for CELC, considering both the potential upside and regulatory/execution risks.
Should Celcuity’s $500 Million Convertible Notes and VIKTORIA-1 Data Shift the CELC Investment Thesis Require Action From Celcuity (CELC) Investors?
Celcuity Inc. recently priced a $500 million convertible senior note offering to repay debt and fund development, while also reporting positive Phase 3 VIKTORIA-1 data for gedatolisib in breast cancer. These developments are expected to strengthen the company's investment narrative, but investors should also consider the added debt and potential for slower-than-expected approvals or uptake. The article encourages investors to form their own verdicts, reminding them that credible views on the company's financial future and fair value can differ.
[Form 4] Celcuity Inc. Insider Trading Activity
Celcuity Inc. director Leo Furcht reported a grant of 1,530 shares of common stock in the form of restricted stock units. This grant, valued at zero dollars per share, is compensation, not a market purchase. After this transaction, Furcht directly holds 12,530 shares, with the restricted stock units vesting by the earlier of the company's 2027 annual meeting or April 30, 2027.
ACT CAPITAL MANAGEMENT, LLC's Celcuity Inc(CELC) Holding History
This article details ACT CAPITAL MANAGEMENT, LLC's historical holdings in Celcuity Inc (CELC). As of March 31, 2026, the firm held 91,675 shares valued at $10.46 million, representing 8.22% of their portfolio. ACT CAPITAL MANAGEMENT, LLC made two purchases of CELC since 2025Q4 at an average price of $90.88, currently showing an estimated loss of $218,360.75 or -2.62%.
TD Asset Management Inc Has $9.73 Million Stake in Celcuity, Inc. $CELC
TD Asset Management Inc significantly increased its stake in Celcuity, Inc. (CELC) by 34% in the fourth quarter, holding 97,526 shares valued at approximately $9.73 million. This comes as institutional ownership in Celcuity reaches 63.33%, and analysts generally maintain a positive outlook with most rating the stock a "Buy" despite recent insider selling. Celcuity also reported better-than-expected quarterly EPS.
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff?
Celcuity Inc. (CELC) shares tumbled 26% after the company reported patient deaths in a late-stage trial for its experimental breast cancer drug, gedatolisib, despite the drug significantly reducing disease progression. The trial results showed reduced risk of disease progression or death by about 50% for gedatolisib regimens compared to the standard treatment, and the company plans to file a supplemental application to the FDA later this year. Retail sentiment on Stocktwits saw CELC stock rise to "extremely bullish" despite the stock's plummeting value.
A Look At Celcuity (CELC) Valuation After Positive VIKTORIA-1 Data And FDA Priority Review
Celcuity (CELC) has seen its share price pull back despite positive Phase 3 VIKTORIA-1 data for gedatolisib and FDA Priority Review, alongside a new US$500 million convertible senior notes offering. While a popular narrative suggests the stock is 25.1% undervalued with a fair value of $116.70 based on future gedatolisib revenue, traditional ratios show it as expensive, trading at a P/B of 79.7x. The article encourages investors to analyze both the optimistic forecasts and existing market multiples to form their own stance.
BNP Paribas Financial Markets Sells 36,648 Shares of Celcuity, Inc. $CELC
BNP Paribas Financial Markets
Geode Capital Management LLC Purchases 64,213 Shares of Celcuity, Inc. $CELC
Geode Capital Management LLC increased its stake in Celcuity, Inc. by 8.4% in the fourth quarter, purchasing 64,213 additional shares to bring its total holding to 830,684 shares valued at approximately $82.9 million. The company is receiving "Moderate Buy" ratings from analysts, despite some concerns about potential share dilution from a recent $500 million convertible senior notes offering and mixed investor reactions to earlier trial results. Insider selling by two directors was also noted, alongside various analyst price target adjustments.
Celcuity Raises $575 Million in 0.25% Convertible Notes Due 2032; Net Proceeds $557 Million
Celcuity (CELC) successfully completed a $575 million offering of 0.250% Convertible Senior Notes due 2032, generating approximately $557 million in net proceeds. Concurrently, the company retired its existing term loan facility of roughly $137.5 million, aiming to reduce financing costs and support future growth and initiatives. This refinancing involved an underwriting agreement with major banks and was governed by a supplemental indenture executed on June 8, 2026.
Preferred dividends of Celcuity Inc. – HAM:7VR
This article states that no preferred dividend information is available for Celcuity Inc. (HAM:7VR) for the specified period. It indicates that the market is closed and provides general financial overview details for the company on the Hamburg Stock Exchange.
Does Celcuity’s (CELC) Low‑Coupon Convertibles Hint at Strategic Caution or Commercial Ambition?
Celcuity Inc. has priced an upsized offering of $500 million in 0.250% convertible senior notes due 2032 to fund its clinical, commercialization, and general corporate needs, including potential acquisitions. This financing comes as the company prepares for possible commercialization of gedatolisib, particularly with its detailed Phase 3 VIKTORIA-1 results in PIK3CA-mutant advanced breast cancer and an upcoming FDA decision. The article questions whether these low-coupon convertibles signal strategic caution or commercial ambition, while emphasizing that the key near-term catalyst remains the FDA decision on July 17, 2026.
Cash from investing activities of Celcuity Inc. – HAM:7VR
This article provides financial data on Celcuity Inc. (HAM:7VR), specifically focusing on its cash from investing activities. It highlights the period value, change, and percentage change of this financial metric. The information is sourced from TradingView, with market data from ICE Data Services and reference data from FactSet.
Operating expenses (excl. COGS) of Celcuity Inc. – HAM:7VR
This article displays the operating expenses (excluding Cost of Goods Sold) for Celcuity Inc., trading under the HAM:7VR symbol on the Hamburg Stock Exchange. The content provides a snapshot of this financial metric, indicating the period, value, and change both in absolute terms and percentage. It is presented within the TradingView platform, with data sourced from ICE Data Services and FactSet.
ETFs Investing in Celcuity Inc. Stocks
This article lists various ETFs that currently hold stocks of Celcuity Inc. (7VR) on the Hamburg Stock Exchange. The ETFs are sorted by their market value and include details such as issuer, management style, expense ratio, assets under management (AUM), price, and 3-year NAV total return. This compilation helps investors identify funds offering diversified exposure to Celcuity Inc. alongside other holdings, potentially lowering risk.
Long term debt to total assets ratio of Celcuity Inc. – LS:A2JAAX
This article focuses on the long-term debt to total assets ratio of Celcuity Inc. (LS:A2JAAX). It appears to be a financial data page from TradingView, providing an overview of the company's financial metric without offering any specific values or detailed analysis in the provided text.
Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets
Celcuity (NasdaqCM:CELC) has expanded its pivotal Phase 3 VIKTORIA-2 trial to include endocrine-sensitive breast cancer patients and is developing a subcutaneous formulation of gedatolisib for increased convenience. This expansion aims to broaden the potential use of its lead asset, especially as the stock has experienced a significant pullback despite a strong year-long gain. Despite current losses and minimal revenue, analyst targets suggest the stock is significantly undervalued.
Celcuity Expands VIKTORIA-2 Trial As Shares Trade Below Targets
Celcuity (NasdaqCM:CELC) has expanded its pivotal Phase 3 VIKTORIA-2 trial to include a new cohort for endocrine-sensitive breast cancer and is developing a subcutaneous formulation of gedatolisib. These updates aim to broaden the potential use of its lead asset. Despite a recent share price decline, the stock trades significantly below analyst targets, with Simply Wall St valuing it at an 88.9% discount to its estimated fair value.
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes ...
Celcuity Inc. announced the pricing of an upsized public offering of $500 million aggregate principal amount of 0.250% convertible senior notes due 2032. The company also granted underwriters a 30-day option to purchase an additional $75 million in notes. Proceeds from the offering are intended for repaying an outstanding loan agreement and for general corporate purposes, including clinical trials, commercial launch expenditures, and potential acquisitions.
Celcuity shares fall despite strong phase 3 breast cancer trial data (CELC)
Despite positive Phase 3 breast cancer trial data, Celcuity's shares experienced a decline. The company's lead drug, gedatolisib, showed promising results in combination with Faslodex and Ibrance for advanced breast cancer, indicating a potential new treatment. The market's reaction, however, was contrary to the positive clinical outcomes.
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Inc. announced the pricing of an upsized public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032, an increase from the previously announced $400,000,000. The company has granted underwriters an option to purchase an additional $75,000,000 aggregate principal amount. The net proceeds are estimated to be approximately $484.3 million and will be used to repay existing debt and for general corporate purposes, including clinical trials and potential acquisitions.
Celcuity Trial Win Raises Questions On Risk, Value And Next Steps
Celcuity reported positive Phase 3 results for its breast cancer drug gedatolisib, showing a significant reduction in disease progression or death, which will lead to seeking regulatory approval. Despite the positive primary endpoints, some patient deaths and outcomes did not fully align with external expectations, raising questions about the drug's benefit-risk profile. Investors are now focused on how regulators will interpret the data, future clinical updates, and the potential impact on Celcuity's valuation and commercialization path.
Celcuity (CELC) Expands Phase 3 VIKTORIA-2 Trial to Include Endocrine-Sensitive Breast Cancer Patients
Celcuity (NASDAQ: CELC) has amended its Phase 3 VIKTORIA-2 clinical trial for gedatolisib, expanding it to include endocrine-sensitive breast cancer patients in addition to the original focus on endocrine-resistant cases. This decision follows encouraging Phase 1b results, aiming to establish gedatolisib as a broad-spectrum treatment. Concurrently, the company is developing a subcutaneous formulation of gedatolisib to improve patient convenience for multi-year treatment plans.
Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032
Celcuity Inc. announced the pricing of an upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032, increasing from the previously announced $400,000,000. The company plans to use the net proceeds, estimated at $484.3 million, to repay existing debt and for general corporate purposes, including clinical trial expenditures and potential acquisitions. Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities are serving as joint book-running managers for the offering.
ASCO26: Celcuity drug halves risk of progression, death versus Novartis' Piqray in PIK3CA breast cancer
This article reports on Celcuity's new drug for PIK3CA-mutated breast cancer, which demonstrated a 50% reduction in the risk of progression or death compared to Novartis' Piqray. The findings were presented at ASCO26, highlighting a significant advancement in treatment options for this specific cancer type.
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. has announced a proposed underwritten public offering of $400 million in convertible senior notes due 2032, with an option for underwriters to purchase an additional $60 million to cover over-allotments. The company plans to use the net proceeds to repay outstanding obligations to Oxford Finance, LLC, and for general corporate purposes, including clinical trial expenses, commercial launch preparations, and potential acquisitions. This offering is subject to market and other conditions, and there is no guarantee of its completion or terms.
ASCO26: Celcuity punished as trial disappoints investors
Celcuity's stock significantly dropped despite positive VIKTORIA-1 trial results for its breast cancer treatment, gedatolisib, which showed strong progression-free survival benefits compared to existing therapies. Investors were reportedly disappointed by the magnitude of improvement, though the company emphasizes the drug's efficacy and superior tolerability. The FDA is expected to deliver a verdict on gedatolisib's approval in mid-July.
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Celcuity's experimental breast cancer drug, gedatolisib, showed promising results in a late-stage trial, halving the risk of death or disease progression in certain patients with PIK3CA-mutated breast cancer. Despite demonstrating significant clinical benefit compared to existing treatments, the data fell short of investors' "lofty expectations," causing Celcuity's shares to drop over 20%. The drug is anticipated to be submitted for expanded use in the third quarter and could reach the market around the same time.
Needham Maintains Celcuity(CELC.US) With Buy Rating, Maintains Target Price $157
Needham has reaffirmed its Buy rating for Celcuity (CELC.US) and maintained its target price of $157. This indicates a continued positive outlook from the analytical firm regarding the company's stock performance and future prospects.
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc. has announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of convertible senior notes due 2032, with an option for underwriters to purchase an additional $60,000,000. The company plans to use the net proceeds to repay an existing loan agreement and for working capital and general corporate purposes, including potential acquisitions. The offering is subject to market conditions, and Jefferies, J.P. Morgan, TD Cowen, and Guggenheim Securities are acting as joint book-running managers.
Celcuity Inc. Announces Public Offering of Convertible Senior Notes Due 2032
Celcuity Inc., a clinical-stage biotechnology company, announced a proposed underwritten public offering of $400,000,000 aggregate principal amount of convertible senior notes due 2032. The company intends to use the net proceeds to repay outstanding obligations and for general corporate purposes, including clinical trial expenditures and potential acquisitions. The offering is subject to market and other conditions, with no assurance as to its completion or terms.
ASCO 2026: Celcuity’s positive phase III gets no love from investors
Celcuity Inc. announced positive phase III data for its pan-PI3K/mTORC1/2 inhibitor gedatolisib at the 2026 American Society of Clinical Oncology annual meeting. Despite the positive results, investors reacted negatively, causing the company's shares to drop 25.7%. The stock fell by $31.54 to $91.42 on June 2, 2026.
